Viamet's candidate for Valley Fever tagged an Orphan Drug by FDA

|About: Viamet Pharmaceuticals... (VMET)|By:, SA News Editor

The FDA designates pending IPO Viamet Pharmaceuticals' (Pending:VMET) IND-stage VT-1598 an Orphan Drug for the treatment of coccidiodomycosis, a fungal lung infection also known as Valley Fever that affects ~150K Americans each year, primarily in the southwestern U.S.

Among the benefits of Orphan Drug status is a seven-year of market exclusivity for the indication, if approved.

Previously: Viamet Pharmaceuticals on deck for IPO (May 6)

Subscribe for full text news in your inbox